VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors

Detailed Description: This is a multicenter, open‐label, multiple‐dose, first inhuman(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval(BOIN) design to escalate doses and determine the maximum tolerated dose(MTD) and/orrecommended phase 2 dose(RP2D) with potential backfill cohorts. The Phase 2a portionconsists of dose optimization followed by cohort expansion to confirm safety andtolerability and further evaluate the efficacy of the selected RP2D in selected solidtumor malignancies treated with VBC117.